JP2011523849A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523849A5 JP2011523849A5 JP2011510744A JP2011510744A JP2011523849A5 JP 2011523849 A5 JP2011523849 A5 JP 2011523849A5 JP 2011510744 A JP2011510744 A JP 2011510744A JP 2011510744 A JP2011510744 A JP 2011510744A JP 2011523849 A5 JP2011523849 A5 JP 2011523849A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding protein
- binding
- binding fragment
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5550008P | 2008-05-23 | 2008-05-23 | |
| US61/055,500 | 2008-05-23 | ||
| PCT/US2009/045182 WO2009143523A1 (en) | 2008-05-23 | 2009-05-26 | Interleukin-21 receptor binding proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011523849A JP2011523849A (ja) | 2011-08-25 |
| JP2011523849A5 true JP2011523849A5 (enExample) | 2012-07-12 |
Family
ID=41112652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510744A Pending JP2011523849A (ja) | 2008-05-23 | 2009-05-26 | インターロイキン−２１受容体結合性タンパク質 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8163884B2 (enExample) |
| EP (1) | EP2297199A1 (enExample) |
| JP (1) | JP2011523849A (enExample) |
| KR (1) | KR20110040773A (enExample) |
| CN (1) | CN102105491A (enExample) |
| AR (1) | AR071885A1 (enExample) |
| AU (1) | AU2009248809A1 (enExample) |
| CA (1) | CA2724915A1 (enExample) |
| CL (1) | CL2009001284A1 (enExample) |
| CO (1) | CO6382184A2 (enExample) |
| IL (1) | IL209328A0 (enExample) |
| MX (1) | MX2010012811A (enExample) |
| MY (1) | MY149448A (enExample) |
| NZ (1) | NZ589330A (enExample) |
| PE (1) | PE20100141A1 (enExample) |
| RU (1) | RU2010152690A (enExample) |
| SA (1) | SA109300315B1 (enExample) |
| TW (1) | TW201000129A (enExample) |
| WO (1) | WO2009143523A1 (enExample) |
| ZA (1) | ZA201008335B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| EP2518084B1 (en) * | 2009-12-25 | 2016-11-30 | Sekisui Medical Co., Ltd. | Method for measuring human insulin and measurement reagent |
| EP2545080B1 (en) * | 2010-03-12 | 2017-05-10 | Alexion Pharmaceuticals, Inc. | Npp1 fusion proteins |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| US20190185559A1 (en) * | 2016-09-02 | 2019-06-20 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating neoplasias |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| EP4162036A1 (en) | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| UA84387C2 (ru) | 1999-03-09 | 2008-10-27 | Займодженетикс, Инк. | Человеческий цитокин как лиганд зальфа рецептора и его применение |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| WO2000069880A1 (en) | 1999-05-18 | 2000-11-23 | Millennium Pharmaceuticals, Inc. | Il-9/il-2 receptor-like molecules and uses thereof |
| ES2279809T3 (es) * | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| ATE346864T1 (de) | 2000-05-11 | 2006-12-15 | Genetics Inst Llc | Mu-1, ein mitglied der cytokine rezeptor familie |
| EP2130919A1 (en) * | 2001-11-05 | 2009-12-09 | ZymoGenetics, Inc. | IL-21 antagonists |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| MXPA04012116A (es) * | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| MXPA05000655A (es) * | 2002-07-15 | 2006-02-22 | Harvard College | Metodos y composiciones para modular el desarrollo y la funcion de las celulas t helper (th). |
| MXPA05009556A (es) * | 2003-03-14 | 2005-11-16 | Wyeth Corp | Anticuerpos contra receptor de il-21 humano y sus usos. |
| RU2005132458A (ru) * | 2003-03-21 | 2006-03-20 | Уайт (Us) | Лечение иммунологических расстройств с использованием агонистов интерлейкина-21/рецептора интерлейкина-21 |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| EP1753458A4 (en) * | 2004-05-19 | 2009-07-22 | Wyeth Corp | MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS |
| MX2007001509A (es) | 2004-08-05 | 2007-03-27 | Wyeth Corp | Antagonismo de la actividad del receptor de interleuquina 21. |
| CN101052419A (zh) * | 2004-08-05 | 2007-10-10 | 惠氏公司 | 拮抗白介素－21受体活性 |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| WO2008081198A1 (en) | 2007-01-05 | 2008-07-10 | Imperial Innovations Ltd | Blood assays for predicting inflammatory responses |
-
2009
- 2009-05-22 AR ARP090101847A patent/AR071885A1/es not_active Application Discontinuation
- 2009-05-22 PE PE2009000719A patent/PE20100141A1/es not_active Application Discontinuation
- 2009-05-23 SA SA109300315A patent/SA109300315B1/ar unknown
- 2009-05-25 CL CL2009001284A patent/CL2009001284A1/es unknown
- 2009-05-25 TW TW098117296A patent/TW201000129A/zh unknown
- 2009-05-26 WO PCT/US2009/045182 patent/WO2009143523A1/en not_active Ceased
- 2009-05-26 RU RU2010152690/10A patent/RU2010152690A/ru not_active Application Discontinuation
- 2009-05-26 US US12/472,209 patent/US8163884B2/en not_active Expired - Fee Related
- 2009-05-26 CN CN200980128968XA patent/CN102105491A/zh active Pending
- 2009-05-26 NZ NZ589330A patent/NZ589330A/xx not_active IP Right Cessation
- 2009-05-26 KR KR1020107028877A patent/KR20110040773A/ko not_active Withdrawn
- 2009-05-26 MX MX2010012811A patent/MX2010012811A/es active IP Right Grant
- 2009-05-26 AU AU2009248809A patent/AU2009248809A1/en not_active Abandoned
- 2009-05-26 CA CA2724915A patent/CA2724915A1/en not_active Abandoned
- 2009-05-26 EP EP09751751A patent/EP2297199A1/en not_active Withdrawn
- 2009-05-26 MY MYPI2010005509A patent/MY149448A/en unknown
- 2009-05-26 JP JP2011510744A patent/JP2011523849A/ja active Pending
-
2010
- 2010-11-15 IL IL209328A patent/IL209328A0/en unknown
- 2010-11-19 ZA ZA2010/08335A patent/ZA201008335B/en unknown
- 2010-12-22 CO CO10160884A patent/CO6382184A2/es not_active Application Discontinuation
-
2012
- 2012-04-23 US US13/453,090 patent/US20120264919A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520989A5 (enExample) | ||
| JP2010535012A5 (enExample) | ||
| JP2022061992A5 (enExample) | ||
| WO2021244089A1 (zh) | 新型冠状病毒（sars-cov-2）刺突蛋白结合分子及其应用 | |
| JP2020023523A5 (enExample) | ||
| JP2006523711A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2009535021A5 (enExample) | ||
| JP2010524489A5 (enExample) | ||
| JP2020500006A5 (enExample) | ||
| JP2023515223A5 (enExample) | ||
| JP2014508511A5 (enExample) | ||
| JP2017029157A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| JP2010529860A5 (enExample) | ||
| JP2021501744A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| JP2012504401A5 (enExample) | ||
| JP2009225799A5 (enExample) | ||
| JP2015535691A5 (enExample) | ||
| TWI455946B (zh) | 抗磷脂醯肌醇蛋白聚糖３抗體 | |
| JP2012524524A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2020537520A5 (enExample) |